Free shipping on all orders over $ 500

Mirococept

Cat. No. M25232

All AbMole products are for research use only, cannot be used for human consumption.

Mirococept Structure
Synonym:

APT070

Size Price Availability
100ug USD 660  USD660 3-4 Weeks
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Mirococept (APT070) is an antibody targeting to complement system C3b/C4b, as well as a membrane-localizing C3 convertase inhibitor. Mirococept reduces the release of C-peptide and pro-inflammatory cytokines, and reduces the infiltration of inflammatory cells. Mirococept reduces intraislet inflammation, which is beneficial to islet transplantation. Mirococept also inhibits increased intestinal and pulmonary vascular permeability to reduce neutrophil influx.

Chemical Information
CAS Number 507453-82-9
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Theodoros Kassimatis, et al. Am J Transplant. Ex vivo delivery of Mirococept: A dose-finding study in pig kidney after showing a low dose is insufficient to reduce delayed graft function in human kidney

[2] Theodoros Kassimatis, et al. Trials. A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial

[3] Fang Xiao, et al. Br J Pharmacol. APT070 (mirococept), a membrane-localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model

[4] Yara Banz, et al. Cardiovasc Res. Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1

[5] Danielle G Souza, et al. Br J Pharmacol. APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury

Related Fusion Proteins Products
Conbercept

Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc.

Evorpacept

Evorpacept (ALX148) is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region designed to enhance the activity of other anti-neoplastic therapies, with minimal additional toxicity.

Belatacept

Belatacept (BMS 224818) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants.

Baminercept

Baminercept (BG 9924) is a lymphotoxin β receptor IgG fusion protein (LTβR-Ig). Baminercept can be used for the research of many autoimmune diseases including primary Sjögren's syndrome (SS) and rheumatoid arthritis (RA) .

Briobacept

Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA).

  Catalog
Abmole Inhibitor Catalog




Keywords: Mirococept, APT070 supplier, Fusion Proteins, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.